An observational study in Post-ERCP Acute Pancreatitis, sponsored by Nicola Frei. Status unknown at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-29.
Sponsored by Nicola Frei · Observational
Pancreatitis is the most common complication after ERCP, although its frequency varies significantly depending on the study from \< 2% up to 40%.
Based upon data from studies that have included unselected patients, post-ercp pancreatitis (PEP) is mild, moderate, and severe in 45%, 44%, and 11% of cases, respectively. Dysfunction of the sphincter Oddi, female gender, younger age, previous history of pancreatitis, prolonged procedure time and pancreatic guidewire passages are well-known independent risk factors for PEP.
This study will assess whether the development of PEP can be predicted by Visual analogue scale (VAS) level 1 hour after ERCP.
752 studies on the registry are indexed under Pancreatitis; 181 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 180 across 277 observational studies indexed under Pancreatitis.
Browse Pancreatitis studies →This is the only study on the registry with Nicola Frei as lead sponsor.
Counted across the registry records on this site, refreshed daily.
All patients scheduled for ERCP for any reason at the study center will be asked for participation.
Exclusion Criteria:
Post procedural pain assessment using the visual analogue scale (VAS) will be performed in patients undergoing ERCP
Association between Pain 1 hour after ERCP
Time frame: 1 hour
Predictive value of VAS for PEP Predictive value of VAS for PEP
Time frame: 1 hour
Association between VAS level and severity of PEP
Time frame: 1 hour
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.